Lv H - Search Results

1

Efficacy and safety of bevacizumab-containing therapy for refractory advanced breast cancer: a retrospective study.

Lv H, Niu L, Zhang M, Zeng H, Zhao S, Wang J, Sun H, Liu Z, Yan M. Lv H, et al. Ann Palliat Med. 2021 Oct;10(10):10997-11005. doi: 10.21037/apm-21-2745. Ann Palliat Med. 2021. PMID: 34763462 Free article.

2

Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.

Yan M, Lv HM, Zhang MW, Cui SD. Yan M, et al. Chin J Cancer Res. 2014 Aug;26(4):486-92. doi: 10.3978/j.issn.1000-9604.2014.08.10. Chin J Cancer Res. 2014. PMID: 25232224 Free PMC article.

3

Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer.

Lv H, Yan M, Zhang M, Niu L, Zeng H, Cui S. Lv H, et al. Chin J Cancer Res. 2014 Dec;26(6):692-7. doi: 10.3978/j.issn.1000-9604.2014.12.13. Chin J Cancer Res. 2014. PMID: 25561767 Free PMC article.

4

Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer.

Zhang M, Yan M, Lv H, Niu L, Zeng H. Zhang M, et al. Among authors: lv h. Ann Palliat Med. 2021 Jan;10(1):238-243. doi: 10.21037/apm-20-2180. Ann Palliat Med. 2021. PMID: 33545761 Free article.

5

Distress Thermometer in breast cancer: systematic review and meta-analysis.

Sun H, Lv H, Zeng H, Niu L, Yan M. Sun H, et al. Among authors: lv h. BMJ Support Palliat Care. 2022 Sep;12(3):245-252. doi: 10.1136/bmjspcare-2021-002960. Epub 2021 May 11. BMJ Support Palliat Care. 2022. PMID: 33975827

6

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer.

Lv H, Yan M, Jiang Z. Lv H, et al. Ther Adv Med Oncol. 2021 May 6;13:17588359211013326. doi: 10.1177/17588359211013326. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33995599 Free PMC article. Review.

7

Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases.

Niu L, Lv H, Zhang M, Zeng H, Wang L, Cui S, Liu Z, Yan M. Niu L, et al. Among authors: lv h. Ann Transl Med. 2021 Aug;9(16):1331. doi: 10.21037/atm-21-3734. Ann Transl Med. 2021. PMID: 34532468 Free PMC article.

8

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.

Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Orlandi A, Ishii N, Takabe K, Franceschini G, Ricci F, Verschraegen C, Liu Z, Zhang M, Lv H, Liu L, Yang X, Xiao H, Gao Z, Li X, Dong F, Chen X, Qiao J, Zhang G. Yan M, et al. Among authors: lv h. Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31. Lancet Oncol. 2022. PMID: 35085506 Clinical Trial.

9

Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer.

Lv H, Niu L, Zhang M, Zeng H, Zhao S, Yan M. Lv H, et al. Chin Med J (Engl). 2022 Sep 5;135(17):2076-2082. doi: 10.1097/CM9.0000000000001969. Chin Med J (Engl). 2022. PMID: 35916549 Free PMC article.

10

Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10-year, single-center, real-world study of 67 cases.

Niu L, Lv H, Zhang M, Zeng H, Fu S, Cui S, Liu Z, Yan M. Niu L, et al. Among authors: lv h. Cancer Med. 2023 May;12(9):10672-10683. doi: 10.1002/cam4.5827. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951543 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,967 results

Search Page

Filters